GDPD5, as well as PLD1 and ChKα, were highly expressed in estrogen receptor negative (ER−) breast cancers, which also displayed higher PC, tCho, and lower GPC in comparison with ER+ cases (165). Here, PLD1 is linked to breast carcinoma.